Endocrinological disturbances in chronic obstructive pulmonary disease

European Respiratory Journal, Supplement

Volumn 22, Issue 46, 2003, Pages

  Creutzberg, E C ^a   Casaburi, R ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Anabolic steroids; Chronic obstructive pulmonary disease; Growth hormone; Insulin like growth factor 1; Testosterone; Thyroid hormone

Indexed keywords

ALBUMIN; ANABOLIC AGENT; CORTICOSTEROID; GONADORELIN; GROWTH HORMONE; LIOTHYRONINE; LUTEINIZING HORMONE; OXANDROLONE; OXYGEN; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN; SOMATOMEDIN C; TESTOSTERONE; THYROID HORMONE; THYROXINE; HORMONE;

AGING; CACHEXIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; ENDOCRINE DISEASE; EXERCISE; FORCED EXPIRATORY VOLUME; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; HYPOXEMIA; MUSCLE MASS; MUSCLE STRENGTH; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; STRESS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THYROID DISEASE; ANIMAL; ARTICLE; HORMONE SUBSTITUTION; METABOLISM;

ANABOLIC AGENTS; ANIMALS; GROWTH HORMONE; HORMONE REPLACEMENT THERAPY; HORMONES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TESTOSTERONE; THYROID HORMONES;

EID: 1542494099     PISSN: 09041850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398-1420.
2. Meek PM, Schwartzstein RM, Adams L, et al. Dyspnea - mechanisms, assessment, and management: A consensus statement. Am J Respir Crit Care Med 1999; 159: 321-340.
3. Hamilton AL, Killian KJ, Summers E, Jones NL. Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med 1995; 152: 2021-2031.
4. Engelen MPKJ, Schols AMWJ, Baken WC, Wesseling GJ, Wouters EFM. Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. Eur Respir J 1994; 7: 1793-1797.
5. Schols AMWJ, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EFM. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147: 1151-1156.
6. Engelen M, Schols A, Lamers RJS, Wouters EFM. Different patterns of chronic tissue wasting among patients with chronic obstructive pulmonary disease. Clin Nutr 1999; 18: 275-280.
7. Schols AMWJ, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EFM. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 819-824.
8. Casaburi R. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Med Sci Sports Exerc 2001; 33: Suppl. 7, S662-670.
9. Gayan-Ramirez G, Vanderhoydonc F, Verhoeven G, Decramer M. Acute treatment with corticosteroids decreases IGF-1 and IGF-2 expression in the rat diaphragm and gastrocnemius. Am J Respir Crit Care Med 1999; 159: 283-289.
10. Scalvini S, Volterrani M, Vitacca M, et al. Plasma hormone levels and haemodynamics in patients with chronic obstructive lung disease. Monaldi Arch Chest Dis 1996; 51: 380-386.
11. Hjalmarsen A, Aasebo U, Birkeland K, Sager G, Jorde R. Impaired glucose tolerance in patients with chronic hypoxic pulmonary disease. Diabetes Metab 1996; 22: 37-42.
12. Mador MJ, Bozkanat E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Respir Res 2001; 2: 216-224.
13. Suchner U, Rothkopf MM, Stanislaus G, Elwyn DH, Kvetan V, Askanazi J. Growth hormone and pulmonary disease. Metabolic effects in patients receiving parenteral nutrition. Arch Intern Med 1990; 150: 1225-1230.
14. Pape GS, Friedman M, Underwood LE, Clemmons DR. The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease. Chest 1991; 99: 1495-1500.
15. Burdet L, de Muralt B, Schutz Y, Pichard C, Fitting JW. Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study. Am J Respir Crit Care Med 1997; 156: 1800-1806.
16. Creutzberg EC, Schols AMWJ, Bothmer-Quaedvlieg FCM, Wouters EFM. Prevalence of an elevated resting energy expenditure in patients with chronic obstructive pulmonary disease in relation to body composition and lung function. Eur J Clin Nutr 1998; 52: 396-401.
17. Baarends EM, Schols AMWJ, Pannemans DL, Westerterp KR, Wouters EFM. Total free living energy expenditure in patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 155: 549-554.
18. Schols AMWJ, Soeters PB, Mostert R, Saris WH, Wouters EFM. Energy balance in chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 143: 1248-1252.
19. Hugli O, Frascarolo P, Schutz Y, Jequier E, Leuenberger P, Fitting JW. Diet-induced thermogenesis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 148: 1479-1483.
20. Dimopoulou I, Ilias I, Mastorakos G, Mantzos E, Roussos C, Koutras DA. Effects of severity of chronic obstructive pulmonary disease on thyroid function. Metabolism 2001; 50: 1397-1401.
21. Bratel T, Wennlund A, Carlstrom K. Impact of hypoxaemia on neuroendocrine function and catecholamine secretion in chronic obstructive pulmonary disease (COPD). Effects of long-term oxygen treatment. Respir Med 2000; 94: 1221-1228.
22. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men - a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3469-3475.
23. Ferrando AA, Tipton KD, Doyle D, Phillips SM, Cortiella J, Wolfe RR. Testosterone injection stimulates net protein synthesis but not tissue amino acid transport. Am J Physiol 1998; 275: E864-871.
24. Tremblay RR, Morales A. Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency. Aging Male 1998; 1: 213-218.
25. Booij A, Biewenga-Booji CM, Huber-Bruning O, Cornelis C, Jacobs JW, Bijlsma JW. Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis. Ann Rheum Dis 1996; 55: 811-815.
26. Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infectcd men. J Clin Endocrinol Metab 2000; 85: 60-65.
27. Semple PD, Beastall GH, Watson WS, Hume R. Serum testosterone depression associated with hypoxia in respiratory failure. Clin Sci 1980; 58: 105-106.
28. English KM, Pugh PJ, Parry H, Scutt NE, Channer KS, Jones TH. Effect of cigarette smoking on levels of bioavailable testosterone in healthy men. Clin Sci 2001; 100: 661-665.
29. Kamischke A, Kemper DE, Castel MA, et al. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J 1998; 11: 41-45.
30. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994; 150: 11-16.
31. Bernard S, LeBlanc P, Whittom F, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 629-634.
32. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156: 1173-1177.
33. Creutzberg EC, Schols AMWJ. Anabolic steroids. Curr Opin Clin Nutr Metab Care 1999; 2: 243-253.
34. Poll van der T, Romijn JA, Endert E, Sauerwein HP. Effects of tumor necrosis factor on the hypothalamic-pituitary-testicular axis in healthy men. Metabolism 1993; 42: 303-307.
35. Creutzberg EC, Wouters EF, Vanderhoven-Augustin IM, Dentener MA, Schols AM. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 1239-1245.
36. Nystrom F, Ekman B, Osterlund M, Lindstrom T, Ohman KP, Arnqvist HJ. Serum leptin concentrations in a normal population and in GH deficiency: negative correlation with testosterone in men and effects of GH treatment. Clin Endocrinol Oxf 1997; 47: 191-198.
37. Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 407-413.
38. Bhasin S, Storer TW, Asbel Sethi N, et al. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 1998; 83: 3155-3162.
39. Verhaar HJJ, Samson MM, Aleman A, Vries WRd, Vreede PLD, Koppeschaar HPF. The relationship between indices of muscle function and circulating anabolic hormones in healthy elderly men. Aging Male 2000; 3: 75-80.
40. Medras M, Jankowska E, Rogucka EA, Lopuszanska M. The effects of sex steroids and some elements of lifestyle on the normal variation of bone mineral content in younger versus older Polish males. Aging Male 2000; 3: 65-74.
41. Iqbal F, Michaelson J, Thaler L, Rubin J, Roman J, Nanes MS. Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function. Chest 1999; 116: 1616-1624.
42. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiological doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335: 1-7.
43. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 2000; 57: 141-147.
44. Schols AMWJ, Soeters PB, Mostert R, Pluymers RJ, Wouters EFM. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med 1995; 152: 1268-1274.
45. Ferreira IM, Verreschi IT, Nery LE, et al. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 1998; 114: 19-28.
46. Yeh SS, DeGuzman B, Kramer T. Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest 2002; 122: 421-428.